CIS Pharma is a privately held biopharmaceutical company based in the Basel Area, Switzerland. We develop next-gen immuno-conjugates, ADCs and radioligand treatments for cancer patients with poor prognosis and prone to high spread of metastases. Our assets include two targeting moieties against CD 171 and CD 276, and a polymer carrier technology to overcome the current limitations of immuno-conjugates. The technology offers high-yield labeling of proteins, increases DAR and creates precision combination therapies.
| Website | http://www.cis-pharma.com |
| Revenue | $6 million |
| Employees | 5 (4 on RocketReach) |
| Founded | 1952 |
| Address | 159 Hauptstrasse, Bubendorf, Basel 4416, CH |
| Phone | +1 848-299-5900 |
| Technologies |
JavaScript
,
HTML
,
PHP
+19 more
(view full list)
|
| Industry | Pharmaceutical Manufacturing, Manufacturing General, Manufacturing |
| Web Rank | 9 Million |
| Keywords | Biopharmaceutical, Cancer Treatment, Oncology, Cancer Therapeutics, Adc, Next Generation Therapeutics, Targeted Therapy, Drug Development, Antibody Drug Conjugates, Precision Medicine, Pharmaceutical Research, Pharmaceutical, Biotechnology, Drug Discovery, Advanced Therapeutics, Clinical Trials |
| Competitors | Roche, Novartis, AbbVie, Pfizer, Sanofi, Amgen, Teva Pharmaceuticals, Sandoz, Aurobindo Pharma LTD, Mylan Belgium +59 more (view full list) |
| SIC | SIC Code 283 Companies, SIC Code 28 Companies |
| NAICS | NAICS Code 325 Companies, NAICS Code 32541 Companies, NAICS Code 3254 Companies, NAICS Code 32 Companies |
Looking for a particular CIS Pharma employee's phone or email?
The CIS Pharma annual revenue was $6 million in 2026.
Rolf Schaefer is the VP Corporate Strategy and Innovation of CIS Pharma.
4 people are employed at CIS Pharma.
CIS Pharma is based in Bubendorf, Basel.
The NAICS codes for CIS Pharma are [325, 32541, 3254, 32].
The SIC codes for CIS Pharma are [283, 28].